http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2302473-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d12b35c0dd9adfb167b3b4f383afe93 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 |
| filingDate | 2006-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a1dba6dae68e7286ed7f7915774b21f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9274be67c376128bf529261b9fc06f9a |
| publicationDate | 2008-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2302473-A1 |
| titleOfInvention | THERAPEUTIC AGENT FOR THE TREATMENT OF BIPOLAR AFFECTIVE DISORDER IN MAMMALS. |
| abstract | Therapeutic agent for the treatment ofnbipolar affective disorder in mammals.n n n Berberine (5,6-dihydro-9,10-dimethoxybenzo [g] -1,3-benzo- dioxolo [5,6-a] quinolizinium), an alkaloid found in nature, inhibits the activity of prolyl oligopeptidase (POP) in a dose-dependent manner. The berberine is able to reach the Central Nervous System where the POP is mainly located. Patients with bipolar affective disorder have increased levels of serum POP activity. Therefore, berberine, in any of its pharmaceutically acceptable acid salts, is useful for the treatment of disorder. bipolar affective den in mammals, including humans. |
| priorityDate | 2006-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.